Theralase Technologies Inc. V.TLT

RE:Perhaps the recent hiring will be to support

[Gustoes]

Thor6570 wrote: The re launch of the TLC 2000  Read the recap link attached !

The TLC-2000 software, firmware and hardware will be redesigned to allow the implementation of a recurring revenue model over a large-scale distribution network.

Theralase in TLC-2000 rethink as sales fail to meet ambitious targets

https://biomedgrid.com/pdf/AJBSR.MS.ID.001200.pdf

Novel therapeutic laser technology that utilizes a biofeedback mechanism, known as Cell Sensing® technology, is able to automatically adjust clinical protocol settings (i.e.: irradiance and exposure time) at the tissue surface to deliver the optimal clinical dose at the afflicted tissue depth, in direct correlation with a patient’s unique physical configuration. The first law of photochemistry, American Journal of Biomedical Science & Research Am J Biomed Sci & Res Copy@ Elizabeth Angelevski DC 469 known as the Grotthuss-Draper Law, states that: “Light has to be absorbed to cause a chemical effect” [12]. Re-framing this law in the aspect of light penetration in tissue, light must be absorbed at tissue depth in order to produce a photochemical reaction at that tissue depth; therefore, more precise, repeatable and reproducible photochemical effects, like the effects that are able to reduce pain, must be exhibited at the disease site or anatomical location of the disease to achieve maximum therapeutic effect.

In scientific evaluation, this revolutionary technology has demonstrated clinically significant pain reduction for a variety of MSK conditions. A retrospective review of the treatment data collected in a cloud database demonstrated significant mean pain score reductions, as measured by a Visual Analog Scale (“VAS”), for ankle, back, knee, foot, hip, neck, shoulder, and wrist pain, as well as for muscle strains. A total of 697 patients, treated for back pain (i.e.: lumbar arthrosis, lumbar disc herniation, lumbar muscle strain, and sciatica), achieved a mean pain score reduction of 30.05% from baseline to last treatment, with an average of 9 treatment sessions. For lower extremity muscle strains (i.e.: gastrocnemius, quadriceps, and hamstrings), 101 patients were treated and evaluated for pain relief. The results showed that with 8 to 9 treatments there was a mean VAS pain score reduction of 31.83%. Undoubtedly, successful pain management relies on the ability of laser technology to deliver an optimal dose of light energy.

Cell Sensing® technology provides more consistent clinical efficacy and higher safety for a patient population suffering from nociceptive and neuropathic pain, by not overdosing or underdosing the patient, especially patients who present with darker skin coloration and/or greater physical size. This type of patient-centric care is, undoubtedly, the future of laser technology